Bluebird Casts Wide Partnering Net To Keep Advancing Cell Therapy
Executive Summary
Bluebird has been an active deal maker as it looks to add tools, targets and technological capabilities to its R&D engine. A pair of August TCR-focused deals, including the latest with Gritstone, continue that strategy.